Navigation Links
Sigma-Tau Pharmaceuticals, Inc. Announces Addition of VP of Finance
Date:7/1/2011

c. is dedicated to creating novel medicines for the unmet needs of patients with rare diseases.  

About Sigma-Tau Pharmaceuticals, Inc.
Sigma-Tau Pharmaceuticals, Inc. is a U.S.-based, wholly owned subsidiary of the Sigma-Tau Group, and is dedicated solely to the global development and commercialization of medicines for patients with rare diseases.  Sigma-Tau Pharmaceuticals, Inc. is based in Gaithersburg, Md.  Since 1989, the company's products have been focused on rare diseases, including kidney disease, certain genetic disorders and cancers.  With more than 7,000 identified rare diseases that affect approximately 25 million patients in the United States, Sigma-Tau places its considerable scientific resources behind the development and commercialization of compounds that benefit the few.  The company has a substantial development program focused on transplant, cancer, inherited genetic disorders, malaria and other areas of unmet medical need.  For more information about the company, visit www.sigmatau.com.


'/>"/>
SOURCE Sigma-Tau Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. DOR BioPharma Announces Private Equity Financing of $3.85 Million with its Partner Sigma-Tau and Other Institutional Investors
2. Sigma-Tau Pharmaceuticals Announces Approval for New Manufacturing Process for ONCASPAR® (Pegaspargase) Primary Ingredient
3. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
4. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
5. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
6. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
7. Sucampo Pharmaceuticals, Inc. Begins Pivotal Phase III Studies of Oral Lubiprostone to Treat Opioid-Induced Bowel Dysfunction (OBD)
8. Symbollon Pharmaceuticals, Inc. Evaluates the Clinical Effects of IoGen(TM) on Fibrocystic Breast Disease
9. Aegerion Pharmaceuticals, Inc. Presents Final Results of Phase II Clinical Trials for AEGR-733 at Drugs Affecting Lipid Metabolism (DALM) 2007 Conference
10. Keryx Biopharmaceuticals, Inc. Announces Positive Preliminary Phase 2 Data on KRX-0401 in Patients with Chemo-Insensitive Rare Sarcoma
11. Quark Pharmaceuticals, Inc. Announces First Systemic siRNA Dosing in Humans
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/1/2015)... Sept. 1, 2015  AccuTec Blades, Inc. today announced ... Blades division.  EPC announced in May 2015 its intent ... Verona, Virginia and Obregon, Mexico ... sale process. Rick Gagliano , ... Blades said, "Our new name, AccuTec Blades, reflects the ...
(Date:9/1/2015)... --NOWDiagnostics Inc., based in Springdale, Ark. , ... Canada , a move that brings the company ... have greater access to information concerning their health. ... blood-based rapid tests that allow health care providers to ... ailments and diseases. ZBx Corporation, a Toronto ...
(Date:9/1/2015)... DALLAS , Sept. 1, 2015 UT ... and distinguished faculty members joined U.S. Representatives ... in a roundtable discussion on the 21 st ... biomedical research currently being considered by the ... faculty – including National Academy of Sciences members, department ...
Breaking Medicine Technology:AccuTec Blades, Inc. Announces Acquisition of Industrial Blades Division from Edgewell Personal Care Company 2NOWDiagnostics Inc. Acquires Canada's ZBx Corporation 2NOWDiagnostics Inc. Acquires Canada's ZBx Corporation 3U.S. Rep. Michael C. Burgess, M.D., hosts roundtable at UT Southwestern to discuss pivotal 21st Century Cures Act and future of biomedical science 2U.S. Rep. Michael C. Burgess, M.D., hosts roundtable at UT Southwestern to discuss pivotal 21st Century Cures Act and future of biomedical science 3U.S. Rep. Michael C. Burgess, M.D., hosts roundtable at UT Southwestern to discuss pivotal 21st Century Cures Act and future of biomedical science 4U.S. Rep. Michael C. Burgess, M.D., hosts roundtable at UT Southwestern to discuss pivotal 21st Century Cures Act and future of biomedical science 5
... Conn., May 15, 2012 /PRNewswire-iReach/ -- Global ... important Cambridge Healthtech Institute conferences: IMVACS – ... August 13 – 15, Cambridge, MA - The ... under one heading: the Seventh Annual Novel Vaccines, Design ...
... Labs, Inc. (OTCQB/OTCBB: GOVX), a biotechnology company that creates, ... results for the three months ended March 31, 2012 ... delighted with recent developments that have strengthened and advanced ... David Dodd. "Our Phase 1/2 therapeutic vaccine trial continues ...
Cached Medicine Technology:Attendees Save up to $350 on CHI Conferences This Summer by Registering Through Global Information 2GeoVax Labs Reports 2012 First Quarter Financial Results 2GeoVax Labs Reports 2012 First Quarter Financial Results 3GeoVax Labs Reports 2012 First Quarter Financial Results 4GeoVax Labs Reports 2012 First Quarter Financial Results 5GeoVax Labs Reports 2012 First Quarter Financial Results 6
(Date:9/1/2015)... ... September 01, 2015 , ... Philanthropic giving in the U.S. has been ... needs. Money for Good 2015, released today by Camber Collective, goes to the root ... to mobilize up to $22B in new philanthropic giving and shift $25B that’s already ...
(Date:9/1/2015)... ... September 01, 2015 , ... As ... Cross and Blue Shield of Minnesota (Blue Cross) has announced Doctor On Demand ... in San Francisco, Doctor On Demand provides immediate access to Board Certified physicians ...
(Date:9/1/2015)... Plainsboro, NJ (PRWEB) , ... September 01, 2015 ... ... up with Cleveland Clinic, ranked a top-five hospital by U.S. News & World ... care for cancer patients. , Editorial and marketing groups within OncLive, which ...
(Date:9/1/2015)... San Francisco, Calif. (PRWEB) , ... September 01, ... ... services to corporations, law firms and government entities, announced today that it has ... as Senior Discovery Consultant. In this capacity, Sanderson will be responsible for ...
(Date:9/1/2015)... ... September 01, 2015 , ... The FSH Society , ... facioscapulohumeral muscular dystrophy (FSHD), will be the beneficiary of a collection of fundraising events ... to raise awareness of the FSH Society and further FSHD research. , ...
Breaking Medicine News(10 mins):Health News:Camber Collective Releases Money for Good 2015 - Revealing Root Causes to Why Charitable Giving Has Been Stuck at 2% GDP Since the 70s 2Health News:Camber Collective Releases Money for Good 2015 - Revealing Root Causes to Why Charitable Giving Has Been Stuck at 2% GDP Since the 70s 3Health News:Blue Cross and Blue Shield of Minnesota names Doctor On Demand as preferred telehealth destination 2Health News:Blue Cross and Blue Shield of Minnesota names Doctor On Demand as preferred telehealth destination 3Health News:OncLive® and Cleveland Clinic Team up to Provide News, Information About Cancer Research and Patient Care 2Health News:OncLive® and Cleveland Clinic Team up to Provide News, Information About Cancer Research and Patient Care 3Health News:Former NFL Standout Scott Sanderson Joins eDiscovery Leader Discovia 2Health News:FSH Society Beneficiary of Variety of Fall Fundraising Events 2Health News:FSH Society Beneficiary of Variety of Fall Fundraising Events 3
... A test developed by physician-scientists at Washington University School ... quickly the ability of Alzheimer,s drugs to affect one ... humans, accelerating the development of new treatments. , Scientists ... given to healthy volunteers reduced production of a substance ...
... Academy of Ophthalmology recommends sport-specific eyewear to prevent devastating injuriesOKLAHOMA ... started out as a routine basketball game his senior year ... a young basketball star who played years of hoops without ... eye by a teammate, Stephen ended up with a large ...
... well for skin appearance in 3 trials , , THURSDAY, April ... seems to improve the healing of skin scars, according to ... TGFa3) administered to their skin before wounding and again 24 ... all the way through the skin of the upper inner ...
... Solutions, Inc. ("Allscripts") announced today information related to ... dividend of $5.23 per share distributed in connection ... on October 10, 2008.(Logo: http://www.newscom.com/cgi-bin/prnh/20081013/AQM041LOGO )At ... that in general the special dividend would be ...
... MISSION VIEJO, Calif., April 9 The Ensign Group, ... its Mt. Ogden Health & Rehabilitation Center in Ogden, ... and Medicaid Services, Special Focus Facility program.(Logo: ... small part of what we,re accomplishing as we strive ...
... Pa., April 9 Kensey Nash Corporation (Nasdaq: ... its earnings results for its third quarter ended March ... April 22, 2009. Joe Kaufmann, President and CEO, ... on Wednesday, April 22, 2009 at 9:00 A.M. Eastern ...
Cached Medicine News:Health News:Test quickly assesses whether Alzheimer's drugs are hitting their target 2Health News:Eye Protection is Essential for Oklahoma Athletes 2Health News:Eye Protection is Essential for Oklahoma Athletes 3Health News:Medication May Improve Scar Healing 2Health News:Allscripts Announces Final Tax Treatment of Special Cash Dividend From the Transactions With Misys plc Completed in October 2008 2Health News:The Ensign Group Successfully Graduates Third Nursing Home From CMS Special Focus Program 2Health News:Kensey Nash Corporation Announces Its Third Quarter 2009 Earnings Release Date and Teleconference 2
Straight shafts with 0.12 mm teeth and tying platform. Serrated handle with polished finish....
Angled 45 degree shafts with 1 x 2 teeth and 5 mm tying platform. Serrated handle with dull finish....
Heavy curved shafts with 2 x 2 teeth and crisscross serrated 6 mm tying platform. Serrated handle with polished finish....
Straight shafts with 1 x 2 teeth and 6 mm tying platform. Wide serrated handle with polished finish....
Medicine Products: